Search for: "Generic Pharmaceutical Association"
Results 1 - 20
of 3,014
Sort by Relevance
|
Sort by Date
28 Apr 2024, 6:31 pm
Bar associations generally operate under the delegated authority of the state’s highest court. [read post]
23 Apr 2024, 1:58 am
On April 22, 2024, the European Federation of Pharmaceutical Industries and Associations (“EFPIA”) issued a statement on the application of the AI Act in the medicinal product lifecycle. [read post]
20 Apr 2024, 9:03 pm
The pharmaceuticals of interest belong to a wide variety of drug classes. [read post]
16 Apr 2024, 8:42 am
While the generic challenger prevailed with respect to the IBS-D patents, the district court found the patents directed toward the use of rifaximin to treat HE to be infringed and not invalid, and ordered that the effective date of a final approval of Norwich’s ANDA should not precede October 2029, which is the latest expiration date associated with the HE patents. [read post]
14 Apr 2024, 7:56 pm
In some cases, generic manufacturers lose money on the drugs, disincentivizing other players in the pharmaceutical industry from stepping in to bolster fragile supply chains. [read post]
13 Apr 2024, 3:33 pm
Of course, for the one “suggested” association for appetite suppressant use among women, the results were even more fragile. [read post]
9 Apr 2024, 2:56 pm
General tax principles typically require that expenses associated with creating assets having useful lives lasting longer than the current tax year are capitalized. [read post]
8 Apr 2024, 9:47 am
Prior antipsychotic drugs have been associated with significant weight gain. [read post]
6 Apr 2024, 8:49 pm
This year's conference co-chairs include Andrei Iancu (Partner, Sullivan & Cromwell LLP and former Director of the USPTO), Brian Malkin (Associate General Counsel, Teva Pharmaceuticals), and Mira Mulvaney (Assistant General Patent Counsel, IP Litigation, Eli Lilly & Company). [read post]
3 Apr 2024, 9:05 pm
To limit damages to the inflation dissipated by corrective disclosures, as required by Dura Pharmaceuticals v. [read post]
3 Apr 2024, 7:18 am
” TRĒ is officially launching its product tday at the annual conference of the Legal Marketing Association in San Diego. [read post]
2 Apr 2024, 9:50 am
As Michael Dorf notes in this post, there are cases in which the maker of a brand-name pharmaceutical challenged the approval of a generic, but this avenue will not always be available. [read post]
1 Apr 2024, 10:58 am
Overall, this is a bad case for pharmaceutical formulary patents. [read post]
29 Mar 2024, 5:21 am
The drug substance is protected by a composition of matter patent and associated SPCs until 2029. [read post]
27 Mar 2024, 5:40 pm
Prioritizing “On-Label” Prescriptions Right now, few insurers cover off-label ketamine therapy (i.e., using generic ketamine, which is only approved as an anesthetic). [read post]
26 Mar 2024, 5:05 pm
Solicitor General Elizabeth Prelogar represented the FDA. [read post]
26 Mar 2024, 3:35 pm
(Katie Barlow) In the bar section, Kristen Waggoner, the president and general counsel of Alliance Defending Freedom, the organization representing the anti-abortion doctors and medical associations that challenged FDA’s actions on mifepristone. [read post]
26 Mar 2024, 12:12 pm
Solicitor General Elizabeth Prelogar argues on behalf of the FDA. [read post]
26 Mar 2024, 7:17 am
Courts have generally rejected standing in such suits. [read post]
25 Mar 2024, 12:39 pm
The drug at the center of the case is known by the generic name mifepristone. [read post]
